1397
Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis.
 patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII: Subject; risk of arterial or venous thrombosis.: Effect; Porcine factor VIII (pFVIII): Treatment; high-titre neutralizing antibodies to human FVIII: Treatment.Disorder; bleeding: Treatment.Disorder; congenital or acquired haemophilia: Treatment.Disorder; Porcine factor VIII: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII: Subject; risk of arterial or venous thrombosis.: Effect; Porcine factor VIII (pFVIII): Treatment; high-titre neutralizing antibodies to human FVIII: Treatment.Disorder; bleeding: Treatment.Disorder; congenital or acquired haemophilia: Treatment.Disorder; Porcine factor VIII: Treatment.Drug